Gene-panel sequencing allows comprehensive analysis of multiple genes simultaneously and is now routinely used in clinical mutation testing of high-risk breast and ovarian cancer patients.
In the past, clinical genetic testing of high-risk individuals, for example familial or early-onset breast cancer cases, was mainly limited to the BRCA1 and BRCA2 genes. Since the development of nextgeneration sequencing techniques, multigene panel testing has been increasingly utilized. Several studies have reported approximately 4% to 6% frequency of mutations in genes other than BRCA1/2 among hereditary breast and ovarian cancer patients. 18 If only BRCA1/2 testing was performed, a large number of patients with potentially actionable mutations would not receive a molecular diagnosis. Furthermore, single-gene tests are not comprehensive as more than 1 risk variants may be segregating in some cancer families and thus a negative test result for a single gene would not be enough for risk stratification. The downside is that the commercially available gene-panels include a vast range of known and putative breast cancer susceptibility genes of which only some have clinical utility. 19 Some panels also include a broad range of cancer predisposition genes that may increase the risk of other malignancies but not breast cancer. Easton et al estimated that currently only BRCA1, BRCA2, TP53, CDH1, PTEN, STK11, NF1, PALB2, CHEK2, ATM, and NBN have sufficient evidence of association with breast cancer to have clinical validity and utility. 19 In addition to these genes, there is clear evidence of association with ovarian cancer for mutations in RAD51C, RAD51D, and BRIP1 but the association with breast cancer is uncertain. 9, 10, 19, 20 Here, we have analyzed the BRCA1, BRCA2, CDH1, PTEN, STK11, TP53, CHEK2, PALB2, RAD51C, and RAD51D genes in 95 high-risk breast or ovarian cancer patients by gene-panel sequencing. We identified a novel RAD51C germline duplication which was further characterized for breast and ovarian cancer risk by screening the duplication in Finnish familial and unselected breast and ovarian cancer patients.
We also performed expression analysis for RAD51C duplication carriers and non-carriers. excluded when calculating the degree of relationship for the breast cancer families. BRCA1/2 screening had been previously performed for 17 patients with 13 patients screened negative for the Finnish founder mutations and 4 patients for the full genes. In addition, 2 patients had a family member previously screened negative for the full BRCA1/2 genes and 1 patient had a family member previously screened negative for the BRCA1/2 founder mutations, these family members were not tested with the gene-panel. 
| MATERIALS AND METHODS

| Subjects
Gene
| Gene-panel sequencing
Ten genes (BRCA1, BRCA2, CDH1, CHEK2, PTEN, STK11, TP53, PALB2, RAD51C, and RAD51D) included in a gene-panel, were analyzed in this study. The SureSelectXT Custom 3-5.9 Mb library kit (Agilent Technology, Santa Clara, CA, USA) was used for DNA capture and the sequencing was performed on the Illumina HiSeq 2500 (Illumina, San Diego, CA, USA; Appendix S1). Identified variants were annotated for their effect on protein coding transcripts and only protein-truncating mutations (ie, nonsense, splicing and frameshift indel mutations) and pathogenic missenses in the 10 studied genes were considered in this study. Copy number variants (CNVs) were identified using an in-house method based on the number of read pairs in short windows over the target regions as described in the Appendix S1. In addition, BRCA1 and BRCA2 large genomic changes were investigated by multiplex ligationdependent probe amplification (MLPA). Pathogenic mutations in the studied genes were verified with Sanger sequencing.
| Duplication characterization
In the CNV analysis, a novel duplication covering the RAD51C exons 1 to 7 was identified. The exact size and location of the duplication was characterized with polymerase chain reaction (PCR) in a germline DNA sample of the carrier patient. The DNA was amplified using a forward primer 5 0 -CTGATCGTGCAGTTTGGGTC-3 0 that binds to RAD51C intron 7 upstream of the duplication breakpoint and a reverse primer 5 0 -TTTTCTCGGCACCAAACCTT-3 0 that binds to the duplicated sequence at the intergenic region upstream of RAD51C.
The PCR products were Sanger sequenced as described in Appendix S1.
| Genotyping
Relatives of the index patient with available DNA samples and the unselected and familial breast and ovarian cancer cohorts and population controls were screened for the duplication with PCR assay. DNA samples were amplified using the same primer pair as in duplication characterization. A second reverse primer 5 0 -AGGGGGAGGATTTACCAGTC-3 0 that binds to RAD51C intron 7 in the non-duplicated region was used as a control to monitor the success of the PCR reaction. The PCR products were run on a 2% agarose gel. Samples containing the duplication displayed 2 bands on the gel and samples without the duplication 1 band ( Figure S1 ). All carriers were confirmed with a second PCR. 
| Gene-expression analysis
| Statistical analyses
Statistical analyses were performed by using the R version 3.0.2 (http://www.r-project.org/). To evaluate the difference in the frequency of the duplication between cases and controls, 2-sided Pvalues were calculated using Fisher's exact test. The difference in the RAD51C expression was evaluated with Student's t test. A P-value <.05 was considered statistically significant.
| RESULTS
| Mutations identified in the gene-panel testing
Out of the 95 patients tested with the gene-panel sequencing, 18 carried clearly pathogenic mutations in the genes included in this study (19%) ( Tables 1 and 2 ). Altogether 12 different mutations were identified in these 18 patients (Table 1) . Protein-truncating BRCA1 mutations, including a large genomic change exon 13 duplication, were detected in 5 patients (5.3%) and BRCA2 mutations in 3 patients (3.2%). The CHEK2 c.1100delC mutation was detected in 7 patients (7.4%), 2 of which also carried the CHEK2 splicing mutation c.444+1G>A. Further analysis of family members showed that the 2 CHEK2 mutations were inherited in different alleles in both of these patients. One pathogenic missense mutation was identified in both the PTEN and TP53 genes. In RAD51C,
the Finnish founder mutation c.837+1G>A was observed in 1 patient who was affected with ovarian and uterine cancer. No deleterious mutations in STK11, PALB2, or RAD51D were detected. In addition to these pathogenic mutations, the low-penetrance CHEK2 c.470T>C p.
Ile157Thr (I157T) missense variant was detected in 6 patients, 2 of which were also BRCA1 carriers and 1 CHEK2 c.1100delC carrier.
Out of the 7 CHEK2 c.1100delC carriers, 6 were women diagnosed with breast cancer at an early age (range 22-39 years) and 1 was a male patient affected with breast and papillary thyroid cancers ( Table 1 ). The PTEN mutation carrier was diagnosed with breast cancer at the age of 39 and her mother and maternal aunt at the age of 63 and 45. The maternal aunt was also diagnosed with synovial sarcoma at the age of 43. After the result of the genetic test, the patient was inspected more carefully. Her head circumference was normal but she had a fibroma, goiter and several trichilemmomas.
The TP53 mutation carrier was diagnosed with bifocal breast cancer at the age of 29. Her maternal grandfather's sister had breast cancer at an old age and maternal aunt colon cancer at the age of 55. The Table 2) . Of the early-onset breast cancer patients, 4 (22%) were mutation positive whereas 20% of TNBC and male breast cancer patients harbored mutations. Of the 20 patients from families previously tested negative for BRCA1/2 mutations, 1 harbored the CHEK2 c.1100delC and c.444+1G>A mutations and 1 had a BRCA1 nonsense mutation which was not previously detected as only the BRCA1/2 founder mutations had been screened.
| Duplication of exons 1 to 7 in RAD51C
In addition to these 12 mutations detected in 18 patients, a novel large heterozygous duplication encompassing the RAD51C exons 1 to 7 was observed in 1 patient. She was diagnosed with breast cancer at the age of 40 and with basal cell carcinoma at the age of 45 and had been previously tested negative for BRCA1/2 mutations. She also had We screened the duplication with a PCR assay in the relatives of the duplication carrier with available DNA samples ( Figure S1 ). Two of the index patient's 3 sisters affected with breast cancer were carriers whereas no duplications were observed in the 3 tested healthy women. Other cancer cases in the family included ovarian cancer and various other cancer types such as Hodgkin lymphoma, colorectal cancer, and prostate cancer among distant relatives, but no samples were available from these patients. We further genotyped the duplication in familial breast and ovarian cancer patients (n = 1149), in unselected cohorts of breast (n = 1729) and ovarian (n = 553) cancer cases, and in healthy female population controls (n = 1273) collected from the same geographic region. Seven additional duplication carriers were identified among cases and none among controls. Two of them were familial breast cancer patients, 3 were unselected breast cancer patients with 1 of them also affected with ovarian cancer, and 2 were unselected ovarian cancer patients. As RAD51C mutations have been previously associated with ovarian cancer, 9,16 we performed subgroup analyses based on family history and personal history of breast and ovarian cancer in order to define the patient group with the strongest association (Table 3) . Altogether, half of the 8 duplication carriers were affected with ovarian cancer or had a family history of ovarian cancer. The duplication was more frequent among ovarian cancer cases (0.5%, P = .032) as well as among patients with a personal or family history of ovarian cancer (0.5%, P = .021) than among population controls (0.0%) ( Table 3 ). The frequency of the duplication among breast cancer patients was 0.2% with a slightly higher 0.3% frequency among familial patients but did not significantly differ from controls (P > .05). All the duplication carriers were negative for the Finnish RAD51C founder mutations c.93delG and c.837+1G>A.
To investigate if the duplication is transcribed into mRNA and whether it affects RAD51C expression we quantified the RAD51C
RNA levels in lymphoblastoid cell lines of 3 carriers and 2 non-carriers. We first measured the RAD51C expression with a probe binding to RAD51C exons 1 to 2 boundary and used ACTB as an endogenous control. Two of the duplication carriers showed significant, 1.52-to 1.68-fold, increased RAD51C expression compared with the noncarrier control sample (P = .020 and P = .013) with the third carrier showing 1.23-fold increase (P = .141) ( Figure 2 and Table S1 ). On average, the 3 carriers had 1.48-fold increased RAD51C expression (P = .074 compared with the 2 non-carries). When the expression was measured using a probe binding to exons 8 to 9 boundary, residing outside of the duplicated area, the expression levels of the carriers and non-carriers were comparable. When the RAD51C exons 8 to 9 probe was used as a control and the expression was measured with the RAD51C exon 1 to 2 probe, the duplication carriers showed 1.21-to 1.66-fold increased expression, 1 of them with significantly increased expression compared with the control (P = .006). On average, the 3 carriers had 1.42-fold expression of the RAD51C ex1-2 (P = .084 compared with the 2 non-carriers).
To further characterize the mRNA produced from the duplication, total RNA was extracted from lymphoblastoid cell lines of 3 duplication carriers and 2 wild type controls. If the translation continues into RAD51C intron 7, a new stop codon is predicted to appear after 18 amino acids p.(Phe323SerfsTer18). Using a forward primer in exon 4 and a reverse primer in exon 7, an expected 300 bp long product was observed in both the controls and carriers ( Figure S2 ).
When using a forward primer at the exon 4 to 5 junction and a reverse primer in intron 7, a novel 663 bp long product was observed in the carriers but not in the controls. Breakpoint:
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RAD51C intron 7 upstream of RAD51C
10bp insertion e x 1 e x 2 e x 3 e x 4 e x 5 e x 6 e x 7 e x 1 e x 2 e x 3 e x 4 e x 5 e x 6 e x 7 e x 8 e x 9 FIGURE 1 Diagram of the RAD51C duplication which starts 31 kb upstream of the RAD51C gene and covers exons 1 to 7. The duplication is highlighted in light red. Exon numbering is based on RAD51C transcript NM_058216.2 and the chromosome positions are according to build hg19 (GRCh37) The patient groups are overlapping and described in more detail in Appendix S1.
a All BC patients from the unselected and familial BC cohorts, 36 (including 1 duplication carrier) are BC + OC patients included also in All OC.
b BRCA1/2-negative familial BC and BC + OC patients from the genepanel sequencing (n = 46) were combined with the genotyped patients including also the patient where the duplication was discovered.
c BC families with no known family history of OC.
d BC families with at least 1 OC case among family members or distant relatives.
e All OC includes unselected and familial OC patients and BC + OC patients from the unselected and familial BC cohorts.
f OC patients with a family history of OC but not BC.
g Any OC includes all patients with personal or family history of OC.
| DISCUSSION
The multigene panel testing of 95 high-risk breast or ovarian cancer patients revealed pathogenic mutations in 18 patients (19%) and a novel RAD51C ex1-7 duplication in 1 patient. While mutations in the most important susceptibility genes BRCA1 and BRCA2 were observed in 5.3% and 3.2% of the patients, respectively, the highest mutation frequency of 7.4% was in CHEK2.
| Mutations in different patient groups and characteristics of the mutation carriers
The only mutation observed in an ovarian cancer case not affected with breast cancer was the RAD51C c.837+1G>A mutation while in patients affected with both breast and ovarian cancer BRCA1 and BRCA2 mutations were observed. This is consistent with an increased risk of ovarian cancer but not breast cancer for RAD51C mutation carriers and an increased risk of both breast and ovarian cancer for BRCA1/2 mutation carriers. 1, 9, 16 The 2 mutations detected among the 10 patients ascertained because of TNBC were in BRCA1, consistent with BRCA1 tumors being often triple-negative. 22 CHEK2 mutations were detected in women diagnosed with breast cancer at an early age and in a man diagnosed with breast and thyroid cancers. This is in line with previous studies indicating that the relative breast cancer risk of CHEK2 c.1100delC carriers decreases by age and showing an association between CHEK2 mutations and the risk of male breast cancer and thyroid cancer. [23] [24] [25] [26] Single PTEN and TP53 mutations were observed in patients who did not present the most typical features of the PTEN hamartoma tumor syndrome (PHTS) or Li-Fraumeni syndrome (LFS) caused by germline mutation in these genes, respectively. PHTS is characterized by macrocephaly, multiple hamartomas, and increased risks of malignant and benign tumors, mainly of the breast, thyroid, and endometrium and LFS by a high risk and an early onset of cancer, most commonly breast cancer, childhood sarcomas, brain tumors, and adrenocortical carcinoma. [2] [3] [4] Interestingly, the identified PTEN mutation carrier had features of Li-Fraumeni-like syndrome with an early-onset breast cancer and a family history of breast cancer and sarcoma.
After the genetic test result, however, she was found to have a fibroma, goiter and trichilemmomas typical for PHTS. The TP53 mutation carrier had an early-onset breast cancer and a family history of breast and colon cancer but did not fulfill the Chompret criteria for women with a single CHEK2 mutation whereas a CHEK2 mutation in a BRCA1 positive woman may not increase the risk beyond that of the BRCA1 mutation alone. 32 Moreover, 2 of the patients previously tested negative for BRCA1/2 mutations were now found to harbor either CHEK2 or BRCA1 mutations and a third patient carried the RAD51C ex1-7 duplication. Lincoln et al compared traditional testing with multigene panel testing and observed deleterious mutations in other breast cancer genes in 2 patients previously tested negative for the familial BRCA1/2 mutation and in 2 BRCA1/2 positive patients. 33 Our results, together with other studies, highlight the advantage of gene-panel testing as information for multiple genes is gained simultaneously.
| RAD51C duplication
Two genomic changes were detected among the patients: the known pathogenic BRCA1 exon 13 duplication and a novel 64 kb long duplication encompassing most of the RAD51C gene. The observed 0.5% frequency of the RAD51C duplication among ovarian cancer patients and its absence among population controls (P = .032) suggest an increased risk of ovarian cancer, consistent with previous studies on RAD51C. 9, 16 The cumulative risk of ovarian cancer by age 80 for RAD51C mutation carriers has been estimated to be >9% whereas there was no evidence for increased breast cancer risk (relative risk
[RR] = 0.91, P = .8). 9 We have previously identified 2 recurrent There are limitations of use of ExAC CNV data as variant calls and frequency estimates are generated from targeted exome sequencing with short reads, and rarity of events may compromise accurate frequency estimates. 35 However, due to the population history of Finland, the allele frequencies differ between different geographical regions and there are genetically distinct subisolates. 36 Thus, geographical matching of cases and controls is important. In our study, the population controls and the cases were collected from the same geographical area. The ExAC CNV carriers may originate from a different region of Finland suggesting also that the detected RAD51C
CNV may be more prevalent in another part of the country. Further validation of the association in larger datasets is warranted.
The identified duplication covers the first 7 exons of RAD51C which are translated into amino acids 1 to 322 in the wild type pro- . 37, 38 The C-terminal amino acids 79 to 376 of RAD51C are needed for the binding to RAD51B, RAD51D, or XRCC3 and a complete β-sheet in the C-terminus is required for a proper folding of the protein. 39 Almost the entire RAD51C region, except for a few Nterminal residues, may be needed for the XRCC3 binding. 40 Thus, the putative truncated RAD51C protein may not be able to bind the other paralogs as it lacks the C-terminal amino acids that are critical to binding. Besides the RAD51 paralogs, RAD51C also directly binds to PALB2 and forms a complex with PALB2, BRCA2, and RAD51. 41 Further functional studies are warranted to characterize the effect of the duplication on the protein level and to establish the level of pathogenicity.
In conclusion, the gene-panel testing of 95 high-risk breast or ovarian cancer patients revealed 12 pathogenic BRCA1, BRCA2, TP53, PTEN, CHEK2, or RAD51C mutations in 18 patients, with 2 patients carrying more than 1 truncating mutation. The RAD51C ex1-7 duplication was identified as novel, likely pathogenic, recurrent mutation in the Finnish population associating with the risk of ovarian cancer and representing a large fraction of all identified RAD51C mutation carriers. This data emphasizes the importance of comprehensive mutation analysis of all the relevant genes simultaneously and including a method to detect CNVs.
